Nyrada (ASX:NYR) has confirmed growing clinical momentum, strengthening finances, and expanding scientific validation for its lead candidate, Xolatryp, as the company positions itself for its next phase of development. …
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 Australian Biotech
Latest Video
New Stories
-
Pharmac announces plan to revise its recently expanded patient advisory function
August 4, 2026 - - Latest News -
Australian company announces agreement with Lilly to trial lung cancer combination
August 4, 2026 - - Latest News -
The complete absence of patient power and agency makes this a health system outlier
August 4, 2026 - - Latest News -
Arrotex Pharmaceuticals appoints experienced industry executive as CMO
August 4, 2026 - - Latest News -
The risk to patients is that new pricing policies could swamp any benefit from the HTA Review
August 4, 2026 - - Latest News -
Potential merger could create a new global oncology powerhouse
August 3, 2026 - - Latest News -
The HTA Review and the 'Abilene paradox' - when everyone argues for reforms that nobody wants
August 3, 2026 - - Latest News